Literature DB >> 25643064

Mycobacterium abscessus. "Pleased to meet you, hope you guess my name...".

David E Griffith1, Barbara A Brown-Elliott, Jeana L Benwill, Richard J Wallace.   

Abstract

Mycobacterium abscessus is a formidable and difficult-to-treat mycobacterial pathogen with multiple drug-resistance mechanisms. The most important of these mechanisms is the presence of an inducible erythromycin methylase (erm) gene, because it confers macrolide resistance. It has recently been found that "M. abscessus" can be split into three species or subspecies based on gene sequence analysis other than the 16S rRNA gene and the presence or absence of a functional erm(41) gene. Several names have been applied to these three organisms, including M. abscessus or M. abscessus subsp. abscessus, Mycobacterium massiliense or M. abscessus subsp. massiliense, and Mycobacterium bolletii or M. abscessus subsp. bolletii. No universally accepted or recognized species or subspecies designations have emerged, and no names have been universally adopted for these organisms. This uncertainty has led to inconsistencies in the medical literature and understandable confusion by clinicians about the appropriate labels for "M. abscessus" isolates. We discuss the complexities involved in mycobacterial species/subspecies identification and taxonomy and suggest possible ways to improve the present state of uncertainty surrounding the labels for "M. abscessus" clinical isolates. We also suggest necessary changes in mycobacterial laboratory processing and reporting procedures for mycobacterial isolates.

Entities:  

Keywords:  Mycobacterium abscessus; Mycobacterium bolletii; Mycobacterium massiliense

Mesh:

Substances:

Year:  2015        PMID: 25643064     DOI: 10.1513/AnnalsATS.201501-015OI

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  35 in total

1.  A rare case of Mycobacterium abscessus subspecies abscessus prosthetic valve endocarditis and the clinical importance of inducible erm(41) gene testing.

Authors:  Norman Beatty; Craig Brown; Tirdad Zangeneh; Mayar Al Mohajer
Journal:  BMJ Case Rep       Date:  2017-06-13

2.  Clinical Characteristics and Treatment Outcomes of Patients with Acquired Macrolide-Resistant Mycobacterium abscessus Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Soyoun Shin; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

3.  "You can't always get what you want…" the Mycobacterium abscessus issue. Name versus function.

Authors:  Adrian M Zelazny; Kenneth N Olivier
Journal:  Ann Am Thorac Soc       Date:  2015-03

4.  Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.

Authors:  Bumhee Yang; Byung Woo Jhun; Seong Mi Moon; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Su-Young Kim; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

5.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease.

Authors:  Hayoung Choi; Su-Young Kim; Hyun Lee; Byung Woo Jhun; Hye Yun Park; Kyeongman Jeon; Dae Hun Kim; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Seung-Heon Lee; Sung Jae Shin; Charles L Daley; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

6.  Production, crystallization and structure determination of a mycobacterial glucosylglycerate hydrolase.

Authors:  Tatiana Barros Cereija; Susana Alarico; Nuno Empadinhas; Pedro José Barbosa Pereira
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-09-01       Impact factor: 1.056

Review 7.  Skin and Soft Tissue Infections Due to Nontuberculous Mycobacteria.

Authors:  Elizabeth Ann Misch; Christopher Saddler; James Muse Davis
Journal:  Curr Infect Dis Rep       Date:  2018-03-19       Impact factor: 3.725

Review 8.  Repositioning rifamycins for Mycobacterium abscessus lung disease.

Authors:  Uday S Ganapathy; Véronique Dartois; Thomas Dick
Journal:  Expert Opin Drug Discov       Date:  2019-06-14       Impact factor: 6.098

9.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

Review 10.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.